MedPath

Age-dependent Effects of Flavanols on Vascular Status

Phase 1
Completed
Conditions
Cardiovascular Diseases
Interventions
Dietary Supplement: Flavanol rich intervention
Dietary Supplement: Flavanol free control
Registration Number
NCT01639781
Lead Sponsor
Heinrich-Heine University, Duesseldorf
Brief Summary

Epidemiological studies suggest that certain foods rich in flavanols, including cocoa products, red wine, and tea, are associated with decreased cardiovascular mortality and morbidity. Dietary interventional studies have corroborated this finding and showed that flavanols can acutely and after sustained ingestion improve surrogate markers of cardiovascular risk including endothelial function. Endothelial dysfunction is the key event in the development and progression of cardiovascular disease. Aging is the major non-modifiable cardiovascular risk factor associated with progressive decline in endothelial function, vascular stiffening and increase in blood pressure. We hypothesize that flavanols can counteract age-dependent vascular changes by interacting with key mechanisms, most prominently endothelial function.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
44
Inclusion Criteria
  • healthy male participants between 18-35 years
  • healthy male participants between 50-80 years
Exclusion Criteria
  • acute inflammation
  • cardiac arrhythmia
  • renal failure
  • heart failure (NYHA II-IV)
  • diabetes mellitus
  • CRP > 1 mg/dl
  • malignant disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
flavanol rich interventionFlavanol rich interventionflavanol rich drink
flavanol free interventionFlavanol free controlflavanol free drink
Primary Outcome Measures
NameTimeMethod
Endothelial functionchange in flow mediated dilatation between first treatment at day 0 and after last treatment at day 14

Flow mediated dilatation (FMD)

Secondary Outcome Measures
NameTimeMethod
NO bioavailability14 days

Measured by CLD

Pulse wave velocity14 days

Measured by SphygmoCor

Erythrocyte deformability14 days

Measured by Laser-assisted Optical Rotation Cell Analyzer (LORCA)

Ambulatory blood pressureblood pressure at day 0 and at day 14

automatical measurements

Heart rate14 days

Measured by ECG

Plasma flavanol metabolitesanalysis of metabolites between first treatment at day 0 and after last treatment at day 14

Measured by HPLC

Microvascular function14 days

Measured by Laserdoppler perfusion imaging (LDPI)

Augmentation index14 days

Measured by SphygmoCor

Trial Locations

Locations (1)

Division of Cardiology, Pulmonology and Vascular Medicine

🇩🇪

Duesseldorf, NRW, Germany

© Copyright 2025. All Rights Reserved by MedPath